Analysis of Reportable Segments
Medtronic PLC operates in 4 segments: Cardiovascular Portfolio; Medical Surgical Portfolio; Neuroscience Portfolio; and Diabetes Operating Unit.
Segment Profit Margin
Medtronic PLC, profit margin by reportable segment
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Cardiovascular Portfolio | 38.32% | 39.50% | 35.74% | 35.53% | 39.39% | 39.29% |
| Medical Surgical Portfolio | 33.87% | 39.08% | 34.58% | 36.45% | 38.48% | 38.39% |
| Neuroscience Portfolio | 40.37% | 42.86% | 38.58% | 37.73% | 40.56% | 39.49% |
| Diabetes Operating Unit | 16.71% | 24.94% | 24.78% | 23.06% | 30.91% | 29.63% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Cardiovascular Portfolio | Cardiovascular Portfolio segment profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. |
| Medical Surgical Portfolio | Medical Surgical Portfolio segment profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. | |
| Neuroscience Portfolio | Neuroscience Portfolio segment profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. | |
| Diabetes Operating Unit | Diabetes Operating Unit segment profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Profit Margin: Cardiovascular Portfolio
Medtronic PLC; Cardiovascular Portfolio; segment profit margin calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 4,435) | 4,512) | 3,850) | 3,719) | 4,532) | 4,461) |
| Net sales | 11,573) | 11,423) | 10,772) | 10,468) | 11,505) | 11,354) |
| Segment Profitability Ratio | ||||||
| Segment profit margin1 | 38.32% | 39.50% | 35.74% | 35.53% | 39.39% | 39.29% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment profit margin = 100 × Segment operating profit ÷ Net sales
= 100 × 4,435 ÷ 11,573 = 38.32%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Cardiovascular Portfolio | Cardiovascular Portfolio segment profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023. |
Segment Profit Margin: Medical Surgical Portfolio
Medtronic PLC; Medical Surgical Portfolio; segment profit margin calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 2,856) | 3,572) | 3,021) | 3,044) | 3,262) | 3,346) |
| Net sales | 8,433) | 9,141) | 8,737) | 8,352) | 8,478) | 8,716) |
| Segment Profitability Ratio | ||||||
| Segment profit margin1 | 33.87% | 39.08% | 34.58% | 36.45% | 38.48% | 38.39% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment profit margin = 100 × Segment operating profit ÷ Net sales
= 100 × 2,856 ÷ 8,433 = 33.87%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Medical Surgical Portfolio | Medical Surgical Portfolio segment profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Profit Margin: Neuroscience Portfolio
Medtronic PLC; Neuroscience Portfolio; segment profit margin calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 3,617) | 3,765) | 3,162) | 2,915) | 3,319) | 3,058) |
| Net sales | 8,959) | 8,784) | 8,195) | 7,725) | 8,183) | 7,743) |
| Segment Profitability Ratio | ||||||
| Segment profit margin1 | 40.37% | 42.86% | 38.58% | 37.73% | 40.56% | 39.49% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment profit margin = 100 × Segment operating profit ÷ Net sales
= 100 × 3,617 ÷ 8,959 = 40.37%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Neuroscience Portfolio | Neuroscience Portfolio segment profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Profit Margin: Diabetes Operating Unit
Medtronic PLC; Diabetes Operating Unit; segment profit margin calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 378) | 583) | 598) | 546) | 739) | 634) |
| Net sales | 2,262) | 2,338) | 2,413) | 2,368) | 2,391) | 2,140) |
| Segment Profitability Ratio | ||||||
| Segment profit margin1 | 16.71% | 24.94% | 24.78% | 23.06% | 30.91% | 29.63% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment profit margin = 100 × Segment operating profit ÷ Net sales
= 100 × 378 ÷ 2,262 = 16.71%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment profit margin | Diabetes Operating Unit | Diabetes Operating Unit segment profit margin ratio improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023. |
Segment Return on Assets (Segment ROA)
Medtronic PLC, ROA by reportable segment
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Cardiovascular Portfolio | 27.63% | 31.14% | 25.62% | 25.05% | 29.33% | 28.95% |
| Medical Surgical Portfolio | 7.88% | 9.67% | 7.68% | 7.67% | 7.92% | 7.78% |
| Neuroscience Portfolio | 19.72% | 22.26% | 18.44% | 17.30% | 19.73% | 20.06% |
| Diabetes Operating Unit | 9.62% | 15.35% | 16.29% | 17.25% | 23.88% | 21.86% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Cardiovascular Portfolio | Cardiovascular Portfolio segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
| Medical Surgical Portfolio | Medical Surgical Portfolio segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. | |
| Neuroscience Portfolio | Neuroscience Portfolio segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. | |
| Diabetes Operating Unit | Diabetes Operating Unit segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment ROA: Cardiovascular Portfolio
Medtronic PLC; Cardiovascular Portfolio; segment ROA calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 4,435) | 4,512) | 3,850) | 3,719) | 4,532) | 4,461) |
| Total assets | 16,051) | 14,490) | 15,027) | 14,844) | 15,453) | 15,407) |
| Segment Profitability Ratio | ||||||
| Segment ROA1 | 27.63% | 31.14% | 25.62% | 25.05% | 29.33% | 28.95% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment ROA = 100 × Segment operating profit ÷ Total assets
= 100 × 4,435 ÷ 16,051 = 27.63%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Cardiovascular Portfolio | Cardiovascular Portfolio segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment ROA: Medical Surgical Portfolio
Medtronic PLC; Medical Surgical Portfolio; segment ROA calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 2,856) | 3,572) | 3,021) | 3,044) | 3,262) | 3,346) |
| Total assets | 36,248) | 36,940) | 39,319) | 39,666) | 41,186) | 43,002) |
| Segment Profitability Ratio | ||||||
| Segment ROA1 | 7.88% | 9.67% | 7.68% | 7.67% | 7.92% | 7.78% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment ROA = 100 × Segment operating profit ÷ Total assets
= 100 × 2,856 ÷ 36,248 = 7.88%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Medical Surgical Portfolio | Medical Surgical Portfolio segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment ROA: Neuroscience Portfolio
Medtronic PLC; Neuroscience Portfolio; segment ROA calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 3,617) | 3,765) | 3,162) | 2,915) | 3,319) | 3,058) |
| Total assets | 18,346) | 16,917) | 17,151) | 16,850) | 16,825) | 15,245) |
| Segment Profitability Ratio | ||||||
| Segment ROA1 | 19.72% | 22.26% | 18.44% | 17.30% | 19.73% | 20.06% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment ROA = 100 × Segment operating profit ÷ Total assets
= 100 × 3,617 ÷ 18,346 = 19.72%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Neuroscience Portfolio | Neuroscience Portfolio segment ROA improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment ROA: Diabetes Operating Unit
Medtronic PLC; Diabetes Operating Unit; segment ROA calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Segment operating profit | 378) | 583) | 598) | 546) | 739) | 634) |
| Total assets | 3,930) | 3,797) | 3,671) | 3,165) | 3,095) | 2,900) |
| Segment Profitability Ratio | ||||||
| Segment ROA1 | 9.62% | 15.35% | 16.29% | 17.25% | 23.88% | 21.86% |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment ROA = 100 × Segment operating profit ÷ Total assets
= 100 × 378 ÷ 3,930 = 9.62%
| Segment profitability ratio | Reportable segment | The company |
|---|---|---|
| Segment ROA | Diabetes Operating Unit | Diabetes Operating Unit segment ROA deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover
Medtronic PLC, asset turnover by reportable segment
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Cardiovascular Portfolio | 0.72 | 0.79 | 0.72 | 0.71 | 0.74 | 0.74 |
| Medical Surgical Portfolio | 0.23 | 0.25 | 0.22 | 0.21 | 0.21 | 0.20 |
| Neuroscience Portfolio | 0.49 | 0.52 | 0.48 | 0.46 | 0.49 | 0.51 |
| Diabetes Operating Unit | 0.58 | 0.62 | 0.66 | 0.75 | 0.77 | 0.74 |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Cardiovascular Portfolio | Cardiovascular Portfolio segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
| Medical Surgical Portfolio | Medical Surgical Portfolio segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. | |
| Neuroscience Portfolio | Neuroscience Portfolio segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. | |
| Diabetes Operating Unit | Diabetes Operating Unit segment asset turnover ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Segment Asset Turnover: Cardiovascular Portfolio
Medtronic PLC; Cardiovascular Portfolio; segment asset turnover calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net sales | 11,573) | 11,423) | 10,772) | 10,468) | 11,505) | 11,354) |
| Total assets | 16,051) | 14,490) | 15,027) | 14,844) | 15,453) | 15,407) |
| Segment Activity Ratio | ||||||
| Segment asset turnover1 | 0.72 | 0.79 | 0.72 | 0.71 | 0.74 | 0.74 |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 11,573 ÷ 16,051 = 0.72
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Cardiovascular Portfolio | Cardiovascular Portfolio segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Asset Turnover: Medical Surgical Portfolio
Medtronic PLC; Medical Surgical Portfolio; segment asset turnover calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net sales | 8,433) | 9,141) | 8,737) | 8,352) | 8,478) | 8,716) |
| Total assets | 36,248) | 36,940) | 39,319) | 39,666) | 41,186) | 43,002) |
| Segment Activity Ratio | ||||||
| Segment asset turnover1 | 0.23 | 0.25 | 0.22 | 0.21 | 0.21 | 0.20 |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 8,433 ÷ 36,248 = 0.23
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Medical Surgical Portfolio | Medical Surgical Portfolio segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Asset Turnover: Neuroscience Portfolio
Medtronic PLC; Neuroscience Portfolio; segment asset turnover calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net sales | 8,959) | 8,784) | 8,195) | 7,725) | 8,183) | 7,743) |
| Total assets | 18,346) | 16,917) | 17,151) | 16,850) | 16,825) | 15,245) |
| Segment Activity Ratio | ||||||
| Segment asset turnover1 | 0.49 | 0.52 | 0.48 | 0.46 | 0.49 | 0.51 |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 8,959 ÷ 18,346 = 0.49
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Neuroscience Portfolio | Neuroscience Portfolio segment asset turnover ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023 not reaching 2021 level. |
Segment Asset Turnover: Diabetes Operating Unit
Medtronic PLC; Diabetes Operating Unit; segment asset turnover calculation
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net sales | 2,262) | 2,338) | 2,413) | 2,368) | 2,391) | 2,140) |
| Total assets | 3,930) | 3,797) | 3,671) | 3,165) | 3,095) | 2,900) |
| Segment Activity Ratio | ||||||
| Segment asset turnover1 | 0.58 | 0.62 | 0.66 | 0.75 | 0.77 | 0.74 |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
1 2023 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 2,262 ÷ 3,930 = 0.58
| Segment activity ratio | Reportable segment | The company |
|---|---|---|
| Segment asset turnover | Diabetes Operating Unit | Diabetes Operating Unit segment asset turnover ratio deteriorated from 2021 to 2022 and from 2022 to 2023. |
Net sales
Medtronic PLC, net sales by reportable segment
US$ in millions
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Cardiovascular Portfolio | 11,573) | 11,423) | 10,772) | 10,468) | 11,505) | 11,354) |
| Medical Surgical Portfolio | 8,433) | 9,141) | 8,737) | 8,352) | 8,478) | 8,716) |
| Neuroscience Portfolio | 8,959) | 8,784) | 8,195) | 7,725) | 8,183) | 7,743) |
| Diabetes Operating Unit | 2,262) | 2,338) | 2,413) | 2,368) | 2,391) | 2,140) |
| Segments | 31,227) | 31,686) | 30,117) | 28,913) | 30,557) | 29,953) |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
Segment operating profit
Medtronic PLC, segment operating profit by reportable segment
US$ in millions
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Cardiovascular Portfolio | 4,435) | 4,512) | 3,850) | 3,719) | 4,532) | 4,461) |
| Medical Surgical Portfolio | 2,856) | 3,572) | 3,021) | 3,044) | 3,262) | 3,346) |
| Neuroscience Portfolio | 3,617) | 3,765) | 3,162) | 2,915) | 3,319) | 3,058) |
| Diabetes Operating Unit | 378) | 583) | 598) | 546) | 739) | 634) |
| Segments | 11,286) | 12,432) | 10,631) | 10,224) | 11,852) | 11,499) |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
Total assets
Medtronic PLC, total assets by reportable segment
US$ in millions
| Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | |
|---|---|---|---|---|---|---|
| Cardiovascular Portfolio | 16,051) | 14,490) | 15,027) | 14,844) | 15,453) | 15,407) |
| Medical Surgical Portfolio | 36,248) | 36,940) | 39,319) | 39,666) | 41,186) | 43,002) |
| Neuroscience Portfolio | 18,346) | 16,917) | 17,151) | 16,850) | 16,825) | 15,245) |
| Diabetes Operating Unit | 3,930) | 3,797) | 3,671) | 3,165) | 3,095) | 2,900) |
| Segments | 74,575) | 72,144) | 75,168) | 74,525) | 76,559) | 76,554) |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).